Literature DB >> 32386897

Comment on "Hearing loss and COVID-19: A note".

Erkan Cure1, Medine Cumhur Cure2.   

Abstract

Entities:  

Mesh:

Year:  2020        PMID: 32386897      PMCID: PMC7192076          DOI: 10.1016/j.amjoto.2020.102513

Source DB:  PubMed          Journal:  Am J Otolaryngol        ISSN: 0196-0709            Impact factor:   1.808


× No keyword cloud information.
Dear Sir, We read with great interest the article by Sriwijitalai W and Wiwanitkit V “Hearing loss and COVID-19: A note” [1]. The authors reported hearing loss in an elderly female patient with novel coronavirus disease 2019 (COVID-19) infection. The patient recovered from COVID-19 infection; however, the hearing loss did not improve. No healing in central hearing loss is likely. Probably, a neuro-auditory problem developed in the patient. Hearing loss in COVID-19 infection has never been reported in the literature so far. We would like to mention how this very rare complication of COVID-19 can develop. The entry point of COVID-19 is the airways and enters the cell by penetrating to the angiotensin-converting enzyme 2 (ACE2) in the lungs. As the cytosolic pH decreases, the ACE2 binding of the virus becomes easier [2]. Since the cytosolic pH decreases with age, the virus causes easier and heavier infection in the elderly [2,3]. The virus can attach to the hemoglobin and penetrates to the erythrocyte [4]. The virus can be transported with erythrocytes or vascular endothelium, possibly infecting all tissues with ACE2 in its structure. There are plenty of ACE2 in the brain and medulla oblongata [5]. The hearing center is in the temporal lobe of the brain. It is also ACE2 here. ACE2 overexpression in the brain, except medulla oblongata, has a positive effect such as anti-inflammatory antioxidant and blood pressure regulator [5]. However, if cytosolic pH is low, an increase in ACE2 causes an increase in viral load [2,3]. Thus, COVID-19 infection may progress more severely. The virus causes excess cytokine to be released when it occupies the hearing center or its surroundings. Thus, it can cause permanent hearing damage by increasing oxidative damage. When the virus infects erythrocytes, it deoxygenates the erythrocytes. If there was an excessive activation of the virus in the hearing center in the brain, this may have caused the hearing center to remain hypoxic and damaged. Considering the age of the patient, it has seen that she is prone to thrombosis. The virus is known to increase thrombosis risk. It contains ACE2 in vascular smooth muscles, thus the virus can infect them. COVID-19 can infect veins that feed the hearing center. It can create a new clot in these vessels or move it by displacement a pre-existing clot. This clot can block vessels that feed the hearing center, causing ischemic damage. It is not an expected finding to affect hearing functions in COVID-19 infection. Due to impaired vascular structure and susceptibility to thrombosis in elderly patients, hearing problems may occur by the mechanisms mentioned above.

Financial disclosure

The authors declare that this study has received no financial support.

Declaration of competing interest

The authors declare that they have no conflict of interest.
  4 in total

Review 1.  Role of the Angiotensin Pathway and its Target Therapy in Epilepsy Management.

Authors:  Shaip Krasniqi; Armond Daci
Journal:  Int J Mol Sci       Date:  2019-02-08       Impact factor: 5.923

2.  Hearing loss and COVID-19: A note.

Authors:  Won Sriwijitalai; Viroj Wiwanitkit
Journal:  Am J Otolaryngol       Date:  2020-04-02       Impact factor: 1.808

3.  Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers may be harmful in patients with diabetes during COVID-19 pandemic.

Authors:  Erkan Cure; Medine Cumhur Cure
Journal:  Diabetes Metab Syndr       Date:  2020-04-15

4.  Comment on "Organ-protective effect of angiotensin-converting enzyme 2 and its effect on the prognosis of COVID-19".

Authors:  Erkan Cure; Medine Cumhur Cure
Journal:  J Med Virol       Date:  2020-06-02       Impact factor: 20.693

  4 in total
  8 in total

1.  A 67-Year-Old Woman with Sudden Hearing Loss Associated with SARS-CoV-2 Infection.

Authors:  Pauliana Lamounier; Victória Franco Gonçalves; Hugo Valter Lisboa Ramos; Débora Aparecida Gobbo; Racine Procópio Teixeira; Paulo César Dos Reis; Fayez Bahmad; Claudiney Cândido Costa
Journal:  Am J Case Rep       Date:  2020-11-03

Review 2.  Otologic dysfunction in patients with COVID-19: A systematic review.

Authors:  Shivesh Maharaj; Martha Bello Alvarez; Sheetal Mungul; Kapila Hari
Journal:  Laryngoscope Investig Otolaryngol       Date:  2020-11-17

Review 3.  Covid-19: pharmacotherapeutic insights on various curative approaches in terms of vulnerability, comorbidities, and vaccination.

Authors:  Rupinder Kaur; Shareen Singh; Thakur Gurjeet Singh; Pragati Sood; Jiki Robert
Journal:  Inflammopharmacology       Date:  2022-01-03       Impact factor: 5.093

4.  Acute Vertigo After COVID-19 Vaccination: Case Series and Literature Review.

Authors:  Paola Di Mauro; Ignazio La Mantia; Salvatore Cocuzza; Pasqua Irene Sciancalepore; Deborak Rasà; Antonino Maniaci; Salvatore Ferlito; Isabella Tundo; Roberta Anzivino
Journal:  Front Med (Lausanne)       Date:  2022-01-06

Review 5.  Vestibular Cochlear Manifestations in COVID-19 Cases.

Authors:  Kathiravan Kaliyappan; Yu-Chen Chen; Vijaya Prakash Krishnan Muthaiah
Journal:  Front Neurol       Date:  2022-03-18       Impact factor: 4.003

6.  Unilateral, permanent hearing loss following severe COVID-19 infection.

Authors:  Sarah Akbar; Darmeena Gopikrishna; Weii Jsim Leong
Journal:  BMJ Case Rep       Date:  2022-09-08

7.  Sudden Sensorineural Hearing Loss Post Coronavirus Disease: A Systematic Review of Case Reports.

Authors:  Abishek Umashankar; Praveen Prakash; Prashanth Prabhu
Journal:  Indian J Otolaryngol Head Neck Surg       Date:  2021-07-10

Review 8.  Hearing Loss in SARS-CoV-2: What Do We Know?

Authors:  Jeyasakthy Saniasiaya
Journal:  Ear Nose Throat J       Date:  2020-08-05       Impact factor: 1.697

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.